ArticleCost effectiveness and resource allocation : C/E2024
Cost-benefit evaluation of advanced therapy lines in metastatic triple-negative breast cancer in Germany.
Amelie Wickmann et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this paperpooled itcites it